3 Price Catalysts For Eli Lilly

Core Insights - Eli Lilly's stock has seen a recovery of approximately 30% since the disappointing drug trial results reported in August, which initially indicated a 50% upside potential [1] Group 1: Company Overview - Eli Lilly specializes in obesity treatments and has been under scrutiny due to recent drug trial results that did not meet expectations [1] Group 2: Market Performance - The stock has realized about 30% of the previously estimated 50% upside in the two months following the trial results [1]